JP2021514956A5 - - Google Patents
Info
- Publication number
- JP2021514956A5 JP2021514956A5 JP2020544456A JP2020544456A JP2021514956A5 JP 2021514956 A5 JP2021514956 A5 JP 2021514956A5 JP 2020544456 A JP2020544456 A JP 2020544456A JP 2020544456 A JP2020544456 A JP 2020544456A JP 2021514956 A5 JP2021514956 A5 JP 2021514956A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- enzyme
- administered
- composition
- trin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023139463A JP2023162344A (ja) | 2018-02-22 | 2023-08-30 | コハク酸セミアルデヒドデヒドロゲナーゼ欠損症（ｓｓａｄｈｄ）を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634092P | 2018-02-22 | 2018-02-22 | |
| US62/634,092 | 2018-02-22 | ||
| PCT/US2019/017623 WO2019164703A1 (en) | 2018-02-22 | 2019-02-12 | Compositions and methods for treating succinic semialdehyde dehydrogenase deficiency (ssadhd) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139463A Division JP2023162344A (ja) | 2018-02-22 | 2023-08-30 | コハク酸セミアルデヒドデヒドロゲナーゼ欠損症（ｓｓａｄｈｄ）を処置するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514956A JP2021514956A (ja) | 2021-06-17 |
| JP2021514956A5 true JP2021514956A5 (enExample) | 2022-03-31 |
Family
ID=67688295
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544456A Pending JP2021514956A (ja) | 2018-02-22 | 2019-02-12 | コハク酸セミアルデヒドデヒドロゲナーゼ欠損症（ｓｓａｄｈｄ）を処置するための組成物および方法 |
| JP2023139463A Pending JP2023162344A (ja) | 2018-02-22 | 2023-08-30 | コハク酸セミアルデヒドデヒドロゲナーゼ欠損症（ｓｓａｄｈｄ）を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139463A Pending JP2023162344A (ja) | 2018-02-22 | 2023-08-30 | コハク酸セミアルデヒドデヒドロゲナーゼ欠損症（ｓｓａｄｈｄ）を処置するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210008225A1 (enExample) |
| JP (2) | JP2021514956A (enExample) |
| KR (1) | KR20200140255A (enExample) |
| AU (1) | AU2019225729A1 (enExample) |
| CA (1) | CA3092035A1 (enExample) |
| WO (1) | WO2019164703A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4440626A4 (en) * | 2021-12-02 | 2025-09-17 | Childrens Medical Ct Corp | GENE THERAPY FOR SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD) |
| CN116478961B (zh) * | 2023-04-27 | 2023-09-15 | 北京因诺惟康医药科技有限公司 | CRISPR/SprCas9基因编辑系统的开发及应用 |
| WO2025042900A1 (en) * | 2023-08-21 | 2025-02-27 | Washington State University | Messenger rna treatment for succinic semialdehyde dehydrogenase deficiency |
-
2019
- 2019-02-12 US US16/969,927 patent/US20210008225A1/en not_active Abandoned
- 2019-02-12 JP JP2020544456A patent/JP2021514956A/ja active Pending
- 2019-02-12 CA CA3092035A patent/CA3092035A1/en active Pending
- 2019-02-12 AU AU2019225729A patent/AU2019225729A1/en not_active Abandoned
- 2019-02-12 KR KR1020207026886A patent/KR20200140255A/ko not_active Ceased
- 2019-02-12 WO PCT/US2019/017623 patent/WO2019164703A1/en not_active Ceased
-
2022
- 2022-03-30 US US17/708,799 patent/US20220331448A1/en not_active Abandoned
-
2023
- 2023-08-30 JP JP2023139463A patent/JP2023162344A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Birkmayer et al. | Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study | |
| US20230070600A1 (en) | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | |
| Singh et al. | Harnessing the mTOR pathway for tuberculosis treatment | |
| JP2021514956A5 (enExample) | ||
| Liu et al. | Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice | |
| Grabinski et al. | Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells | |
| Thangamani et al. | Repurposing celecoxib as a topical antimicrobial agent | |
| Zhu et al. | Mechanism of mitophagy and its role in sepsis induced organ dysfunction: A review | |
| Yu et al. | Autophagy: Novel applications of nonsteroidal anti‐inflammatory drugs for primary cancer | |
| Park et al. | Understanding metabolic regulation between host and pathogens: new opportunities for the development of improved therapeutic strategies against Mycobacterium tuberculosis infection | |
| Kasirzadeh et al. | β‐Sitosterol alters the inflammatory response in CLP rat model of sepsis by modulation of NFκB signaling | |
| Villégier et al. | Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| Yang et al. | Mangiferin alleviates hypertension induced by hyperuricemia via increasing nitric oxide releases | |
| JP2019511496A5 (enExample) | ||
| Zong et al. | 18α‐glycyrrhetinic acid extracted from G lycyrrhiza radix inhibits proliferation and promotes apoptosis of the hepatic stellate cell line | |
| CA2614885C (en) | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | |
| Sun et al. | The role of extracellular vesicles in podocyte autophagy in kidney disease | |
| CN109069467B (zh) | 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途 | |
| Weir et al. | mTOR inhibition: the learning curve in kidney transplantation | |
| Trösch et al. | First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation | |
| WO2008063563B1 (en) | Methods of treating keratin hyperproliferation disorders using mtor inhibitors | |
| Pan et al. | Trehalose ameliorates autophagy dysregulation in aged cortex and acts as an exercise mimetic to delay brain aging in elderly mice | |
| JPH11501934A (ja) | ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物 | |
| US20180289694A1 (en) | Pharmaceutical combination of everolimus with dactolisib |